What the label lists and what reports show
Atezolizumab side effects
Atezolizumab's FDA label: “Most common adverse reactions (≥ 20%) with TECENTRIQ as a single-agent are fatigue/asthenia, decreased appetite, nausea, cough, and dyspnea.” FAERS holds 38,607 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is pyrexia (1,749 reports).
- No generic listed
Check it at the source: the atezolizumab FDA label on DailyMed (effective May 20, 2026, Genentech, Inc.); the FDA FAERS public dashboard.
What does the patient leaflet say about side effects?
From the patient leaflet: What are the possible side effects of TECENTRIQ?TECENTRIQ can cause serious side effects, including: See " What is the most important information I should know about TECENTRIQ? " The most common side effects of TECENTRIQ when used alone include: feeling tired or weak decreased appetite nausea cough shortness of breath The most common side effects of TECENTRIQ when used in lung cancer with other anti-cancer medicines include: feeling tired or weak nausea hair loss constipation diarrhea decreased appetite The most common side effects of TECENTRIQ when used in hepatocellular carcinoma with bevacizumab include: high blood pressure feeling tired or weak too much protein in the urine The most common side effects of TECENTRIQ when used in melanoma with cobimetinib and vemurafenib include: skin rash joint, muscle, or bone pain feeling tired or weak liver injury fever nausea itching swelling of legs or arms mouth swelling (sometimes with sores) low thyroid hormone levels sunburn or sun sensitivity TECENTRIQ may cause fertility problems in females, which may affect the ability to have children. […]
Source: FDA drug label, Genentech, Inc., effective May 20, 2026 (SPL set 6fa682c9-a312-4932-9831-f286908660ee), via openFDA; the full label on DailyMed
What does the label list?
From the label: adverse reactionsMost common adverse reactions (≥ 20%) with TECENTRIQ as a single-agent are fatigue/asthenia, decreased appetite, nausea, cough, and dyspnea.
Table 8: Adverse Reactions Occurring in ≥15% of Patients with NSCLC Receiving TECENTRIQ in IMpower150
| Reaction | All Grades (%) | Grades 3–4 (%) | All Grades (%) | Grades 3–4 (%) |
|---|---|---|---|---|
| Neuropathy Includes neuropathy peripheral, peripheral sensory neuropathy, hypoesthesia,… | 56 | 3 | 47 | 3 |
| Headache | 16 | 0.8 | 13 | 0 |
| Fatigue/Asthenia | 50 | 6 | 46 | 6 |
| Pyrexia | 19 | 0.3 | 9 | 0.5 |
| Alopecia | 48 | 0 | 46 | 0 |
| Rash Includes rash, rash maculo-papular, drug eruption, eczema, eczema asteatotic,… | 23 | 2 | 10 | 0.3 |
| Myalgia/Pain Includes pain in extremity, musculoskeletal chest pain, musculoskeletal… | 42 | 3 | 34 | 2 |
| Arthralgia | 26 | 1 | 22 | 1 |
| Nausea | 39 | 4 | 32 | 2 |
| Diarrhea Includes diarrhea, gastroenteritis, colitis, enterocolitis | 33 | 6 | 25 | 0.5 |
| Constipation | 30 | 0.3 | 23 | 0.3 |
| Vomiting | 19 | 2 | 18 | 1 |
| Decreased appetite | 29 | 4 | 21 | 0.8 |
| Hypertension | 25 | 9 | 22 | 8 |
| Cough | 20 | 0.8 | 19 | 0.3 |
| Epistaxis | 17 | 1 | 22 | 0.3 |
| Proteinuria Data based on Preferred Terms since laboratory data for proteinuria were not… | 16 | 3 | 15 | 3 |
Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.
From the label: adverse reactions, continuedThe following clinically significant adverse reactions are described elsewhere in the labeling: Severe and Fatal Immune-Mediated Adverse Reactions [see Warnings and Precautions (5.1) ] Infusion-Related Reactions [see Warnings and Precautions (5.2) ] Complications of Allogeneic HSCT after PD-1/PD-L1 Inhibitors [see Warnings and Precautions (5.3) ] TECENTRIQ as a single-agent Most common adverse reactions (≥ 20%) with TECENTRIQ as a single-agent are fatigue/asthenia, decreased appetite, nausea, cough, and dyspnea. ( 6.1 ) TECENTRIQ in combination with other antineoplastic drugs Most common adverse reactions (≥ 20%) in patients with NSCLC and SCLC are fatigue/asthenia, nausea, alopecia, constipation, diarrhea, and decreased appetite. ( 6.1 ) TECENTRIQ in combination with bevacizumab Most common adverse reactions (≥ 20%) in patients with HCC are hypertension, fatigue and proteinuria. ( 6.1 ) TECENTRIQ in combination with cobimetinib and vemurafenib Most common adverse reactions (≥ 20%) with TECENTRIQ in patients with melanoma are rash, musculoskeletal pain, fatigue, hepatotoxicity, pyrexia, nausea, pruritus, edema, stomatitis, hypothyroidism, and photosensitivity reaction.
Source: FDA drug label, Genentech, Inc., effective May 20, 2026 (SPL set 6fa682c9-a312-4932-9831-f286908660ee), via openFDA; the full label on DailyMed
What do FAERS reports show?
38,607 reports list atezolizumab among the medicines taken, each a report of something that happened, not proof the medicine caused it; 9,820 are coded as a death and 16,374 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 20 reactions below, 19 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.
Reports received each year
The 25 most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms
What next?
- Atezolizumab: the full record
- label, generics, price, shortages, recalls
- Report a side effect to the FDA
- MedWatch
- Side effects hub
- the most reported medicines and reactions